HFpEF Outcomes Improve With Semaglutide in T2DM and Obesity
Mar 7, 2025 · HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.
Sarah A. Steimel, PhD, Author at The Cardiology Advisor
Jun 14, 2024 · Sarah A. Steimel joined Haymarket as a Medical Editor for Psychiatry Advisor after completing her PhD in neuroscience at Dartmouth College in 2023. She writes and edits medical …
JAK Inhibitors Linked to Increased Reporting of Adverse Cardiovascular ...
Jul 26, 2024 · Results of a global postmarketing study confirmed the association between JAK inhibitors and adverse cardiovascular events among patients with RA.
Decrease in Mortality Rate for Atherosclerotic Cardiovascular Disease ...
May 15, 2024 · The decreasing trend in mortality has slowed in the past 2 decades among US adult patients with atherosclerotic cardiovascular disease.
Childhood Cancer Treatments May Increase Diabetes Risk
Feb 25, 2025 · Childhood cancer treatments, specifically total body irradiation, were associated with increased risk of developing diabetes among cancer survivors.
Omecamtiv Mecarbil May Improve Cardiac Function in Heart Failure …
Nov 10, 2015 · ORLANDO, Fla. — Omecamtiv mecarbil, a novel selective cardiac myosin inhibitor, may improve cardiac function in patients with heart failure and reduced ejection fraction (HFrEF), …
January 2025: Notable Drug Approvals - The Cardiology Advisor
Feb 11, 2025 · The following are some of the notable drug approvals that occurred in January 2025. Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that selectively …
EEG of Dying Man Shows Unexpected Activity in Brain Area Tied to …
Apr 15, 2022 · Unexpected brain activity was identified in continuous EEG recordings of an older male patient who died from a heart attack, challenging when life and death actually end.
AHA Examines CVD and Breast Cancer Relationship
Apr 19, 2018 · The American Heart Association has released a scientific statement examining the relationship between cardiovascular disease and breast cancer.
Semaglutide Associated With Improved Symptoms in Obesity-Related …
Apr 26, 2024 · Semaglutide is associated with significant improvement in HF-related symptoms and reductions in body weight in patients with obesity-related HFpEF.